Angiotensin receptor blockers: current status and future prospects.
Kumar
Sumit
S
Dallas Nephrology Associates, Texas Blood Pressure Institute, University of Texas Southwestern Medical School, Dallas, TX, USA.
Ram
C Venkata S
CV
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005544:Forecasting; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors